EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieMultizentrische Studie

Comparison of Long Term Effects of Treatment of Different CFTR Modulators in People With Cystic Fibrosis

Paulina Famulska iD, Barbara Więckowska, Beata Narożna, Ewa Sapiejka iD, Marta Osińska iD, Anna Musiał, Aleksandra Szczepankiewicz, Katarzyna Tąpolska-Jóźwiak iD, Anna Wiesner iD, Anna Steinert-Dymecki, Maria Jóźwiak iD, Irena Wojsyk-Banaszak iD

Pediatric Pulmonology · 2026

DOI: 10.1002/ppul.71681 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pediatric Pulmonology, 2026. Verfasst von Paulina Famulska und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Cystic Fibrosis, Polanki Children's Hospital, Gdańsk, Poland. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quinolones, Aminophenols, Benzodioxoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cystic fibrosis transmembrane conductance regulator modulators (CFTRm) represent a breakthrough in the treatment of people with cystic fibrosis (PwCF), offering improvements in health outcomes and quality of life (QoL) previously unattainable.

Objective

To descriptively evaluate 12‐month outcomes during treatment with three CFTRm therapies in a real‐world cohort of children and adults with CF.

Methods

This prospective, observational study included 146 PwCF aged 2–56 years treated at two Polish CF centres. Patients received lumacaftor/ivacaftor (LUM/IVA), tezacaftor/ivacaftor (TEZ/IVA) or elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA). Assessments were conducted at baseline and every 3 months over 12 months. Parameters evaluated included spirometry, impulse oscillometry (IOS), lung clearance index (LCI), anthropometric data, serum vitamin D3, sweat chloride (SwCl), lung imaging (Brasfield score), general clinical status – Schwachman‐Kulczycki (S‐K score), and quality of life (QoL). Statistical analyses were performed using the software R (v. 4.4.1).

Results

Most parameters improved over time, with response magnitude varying by treatment. Significant improvements were observed in forced expiratory volume in 1 s (FEV 1 ), forced vital capacity (FVC), maximal expiratory flow at 50% of vital capacity (MEF 50 ), LCI, most IOS parameters, SwCl, anthropometric parameters, Brasfield and S‐K scores. Vitamin D3 concentrations and resistance at 5 Hz (R5) did not change significantly. All therapies led to better QoL.

Conclusions

CFTRm – particularly ELX/TEZ/IVA – demonstrated substantial clinical benefits across age groups. The treatment effect varied over time in the majority of patients. Different CFTRm's impact on respiratory function, nutritional status, and well‐being underscores the importance of personalized approaches in CF care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuinolonesAminophenolsBenzodioxolesAminopyridinesCystic Fibrosis Transmembrane Conductance RegulatorIndolesQuinuclidinesChloride Channel AgonistsHumansFemaleMaleChild, PreschoolChildProspective StudiesAdolescentQuality of LifeAdultTreatment OutcomeMiddle AgedYoung AdultDrug CombinationsPyrrolidinesPyrazolesRespiratory Function TestsPyridinesQuinolines

Stichwörter der Autor:innen

CFTR modulatorscystic fibrosispulmonary function improvementquality of life in CF patientsreal‐world clinical outcomes

Substanzen

QuinolonesAminophenolsBenzodioxolesAminopyridinesCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsIndolesQuinuclidineslumacaftor, ivacaftor drug combinationPyrrolidines

Autor:innen und Institutionen

  • Department of Paediatrics and Cystic Fibrosis, Polanki Children's Hospital, Gdańsk, Poland.
  • Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznań, Poland.
  • Department of Paediatric Pulmonology, Allergy and Clinical Immunology, Poznan University of Medical Sciences, Poznań, Poland.
  • Department of Diabetology, Auxology and Paediatric Obesity, Poznan University of Medical Sciences, Poznań, Poland.

ORCID-Profile: Paulina Famulska, Ewa Sapiejka, Marta Osińska, Katarzyna Tąpolska-Jóźwiak, Anna Wiesner, Maria Jóźwiak, Irena Wojsyk-Banaszak

Zitieren

APA

Famulska, P., Więckowska, B., Narożna, B., Sapiejka, E., Osińska, M., Musiał, A., Szczepankiewicz, A., Tąpolska-Jóźwiak, K., Wiesner, A., Steinert-Dymecki, A., Jóźwiak, M., & Wojsyk-Banaszak, I. (2026). Comparison of Long Term Effects of Treatment of Different CFTR Modulators in People With Cystic Fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71681

Vancouver

Famulska P, Więckowska B, Narożna B, Sapiejka E, Osińska M, Musiał A, et al. Comparison of Long Term Effects of Treatment of Different CFTR Modulators in People With Cystic Fibrosis. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71681

BibTeX
@article{Famulska2026,
  author = {Famulska, Paulina and Więckowska, Barbara and Narożna, Beata and Sapiejka, Ewa and Osińska, Marta and Musiał, Anna and Szczepankiewicz, Aleksandra and Tąpolska-Jóźwiak, Katarzyna and Wiesner, Anna and Steinert-Dymecki, Anna and Jóźwiak, Maria and Wojsyk-Banaszak, Irena},
  title = {Comparison of Long Term Effects of Treatment of Different CFTR Modulators in People With Cystic Fibrosis},
  journal = {Pediatric Pulmonology},
  year = {2026},
  doi = {10.1002/ppul.71681}
}
Kostenlos starten →